PCM-075 Expanding Pipeline

Integrating Technology in Tumor Genomics with the Development of Precision Cancer Therapeutics

Our deep understanding of tumor genomics may allow for effective targeting of appropriate cancer patients, which, in turn, may improve patient care and outcomes.

Optimizing the Development of PCM-075

We have significant experience and expertise with biomarkers and technology in cancer, including AML. We are the patent holder of NPM1 for diagnosis and monitoring of patient response. NPM1-mutated AML is a genetic marker in leukemia and accounts for approximately one-third of all AML patients. We believe that developing precision cancer therapeutics with biomarkers offers improved commercial advantages.